Mads has significant clinical and business expertise within hematology and oncology as well as a robust clinical experience in planning and execution of clinical trials both from academia and the pharmaceutical industry including real-world evidence projects.
Key Areas Of Expertise
- In-depth knowledge of hematology and malignant lymphoma
o Board certified specialist in hematology and medicine - Real-World Evidence expertise
o RWD strategy development
o Execution support of RWD projects - Clinical development plan strategy and design
Before NDA
Mads has been the chairman of the EORTC Lymphoma Group for 3 years and external clinical assessor for the Danish Medicines Agency for more than 10 years doing EMA assessments and participating in EMA Scientific Advice’s for the Danish CHMP member.
He was Head of the Lymphoma and Myeloma Clinic at the University Hospital Rigshospitalet, Department of Hematology, Copenhagen, Denmark for 10 years. Before that he was resident at the Finsen Institute, Departments of Hematology (University Hospitals of Copenhagen and Herlev); the Department of Clinical Chemistry (Hillerød Hospital, Denmark) and consultant at the Department of Oncology and Hematology (Hillerød Sygehus, Hillerød).
Since 2008 he has worked in the pharmaceutical industry as Medical Advisor, Genmab A/S; Medical Advisor, Amgen AB Denmark; Therapeutic Head Oncology, Amgen AB, Nordic & Baltic and Medical Director Denmark and Norway, Amgen AB.
Since 2021 founder and managing director of ZEMA Pharma Consulting.
Between 1999 -2008 Mads has been member of the EORTC Lymphoma Group and Chairman between 2005 – 2008. He was also a member of The Nordic Lymphoma Group 1998-2008.
He has published 46 papers in peer reviewed journals, and is a Doctor of Medical Sciences.
Recent Publications
